StreetInsider.com News Articles

Lobe Sciences closes $2.16M private placement for S-100 drug program

Mon, 31 Aug 2026 19:00:20 -0400

Lobe Sciences Ltd. (CSE: LOBE, OTCQB: LOBEF, Frankfurt: LOBE.F) has closed a two-tranche non-brokered private placement, issuing a total of 25,411,762 common shares at $0.085 per share for gross proceeds of $2,160,000, according to a company statement.

The first tranche, closed Aug. 19, 2026, raised $2,100,000 through the issuance of 24,705,880 shares. A second tranche, driven by additional investor demand, raised $60,000 through 705,882 shares.

The company said proceeds will be used for working capital, general corporate purposes, and to advance its S-100 drug candidate for the treatment of sickle cell disease. A portion will be directed to its subsidiary, Applied Lipid

Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private Placement

Mon, 31 Aug 2026 19:00:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, BC / ACCESS Newswire / August 31, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, is pleased to announce closing of the second tranche of its previously announced non-brokered private placement offering of common shares in the capital of the Company ("Common Shares") at a price of $0.085 per Common Share (the "Private Placement").

The Company closed the first tranche of the Private Placement

Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private Placement

Mon, 31 Aug 2026 19:00:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

The Company closed the first tranche of the Private Placement

Lobe Sciences upsizes private placement to $2.16M

Fri, 28 Aug 2026 19:00:16 -0400

Lobe Sciences Ltd. (CSE: LOBE, OTCQB: LOBEF, Frankfurt: LOBE) has announced an upsize to its non-brokered private placement of common shares at $0.085 per share.

The company closed the first tranche of the offering on August 19, 2026, issuing 24,705,880 shares for gross proceeds of $2,100,000. A second tranche of 705,882 shares is planned, targeting approximately $60,000 in additional gross proceeds. If the second tranche closes, the total offering will amount to 25,411,762 shares for aggregate gross proceeds of $2,160,000.

According to a press release, the company intends to use the proceeds for working capital, general corporate purposes, and to advance its

Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement

Fri, 28 Aug 2026 19:00:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

VANCOUVER, BC / ACCESS Newswire / August 28, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, is pleased to announce an upsize to its previously announced non-brokered private placement offering of common shares in the capital of the Company ("CommonShares") at a price of $0.085 per Common Share (the "Private Placement").

The Company closed the first tranche of the Private Placement on August 19, 2026

Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement

Fri, 28 Aug 2026 19:00:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

The Company closed the first tranche of the Private Placement on August 19, 2026

Lobe Sciences Expands Leadership Team with New CFO Appointment

Fri, 28 Aug 2026 08:00:00 -0400

Dr. David Kideckel, PhD, MBA, joins as Chief Financial Officer, bringing nearly two decades of life sciences, capital markets and corporate advisory experience
Current CFO, Mirza Rahimani, transitions to Vice President of Finance, providing continuity across financial reporting and operations
Appointment strengthens Lobe's leadership team as the Company advances L-130, its differentiated conjugated psilocin therapeutic being developed at sub-hallucinogenic doses for chronic cluster headache

VANCOUVER, BC / ACCESS Newswire / August 28, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company advancing differentiated therapeutics for serious conditions with

Lobe Sciences Expands Leadership Team with New CFO Appointment

Fri, 28 Aug 2026 08:00:00 -0400

Dr. David Kideckel, PhD, MBA, joins as Chief Financial Officer, bringing nearly two decades of life sciences, capital markets and corporate advisory experience
Current CFO, Mirza Rahimani, transitions to Vice President of Finance, providing continuity across financial reporting and operations
Appointment strengthens Lobe's leadership team as the Company advances L-130, its differentiated conjugated psilocin therapeutic being developed at sub-hallucinogenic doses for chronic cluster headache

Lobe Sciences closes $2.1M private placement for sickle cell program

Thu, 20 Aug 2026 08:01:10 -0400

Lobe Sciences Ltd. (CSE: LOBE, OTCQB: LOBEF, Frankfurt: LOBE) has closed a non-brokered private placement, issuing 24,705,880 common shares at $0.085 per share for gross proceeds of approximately $2,100,000, according to a company statement.

The Vancouver-based clinical-stage biopharmaceutical company said proceeds will be used for working capital and general corporate purposes, with a portion directed to its wholly owned subsidiary, Applied Lipid Technologies, Inc., to advance its S-100 drug candidate for sickle cell disease toward human clinical trials. The company said it has already procured the active pharmaceutical ingredient required for those studies.

All securities issued under the placement are subject to

Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement

Thu, 20 Aug 2026 08:00:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

VANCOUVER, BC / ACCESS Newswire / August 20, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, is pleased to announce the closing of its previously announced non-brokered private placement offering of 24,705,880 common shares in the capital of the Company ("Common Shares") at a price of $0.085 per Common Share, for aggregate gross proceeds of approximately $2,100,000 (the "Private Placement").

The Company intends to use

Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement

Thu, 20 Aug 2026 08:00:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

The Company intends to use

Lobe Sciences Reports Third Quarter 2026 Financial Results

Tue, 18 Aug 2026 08:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / August 18, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, today announced its unaudited interim financial results for the third quarter of fiscal 2026 ended May 31, 2026 ("Q3 2026").

During the quarter, the Company continued to advance its development pipeline while maintaining a disciplined approach to capital allocation. Management believes the progress achieved in Q3 2026 reflects continued execution on its strategic priorities and reinforces the Company's focus on building long-term shareholder

Lobe Sciences Reports Third Quarter 2026 Financial Results

Tue, 18 Aug 2026 08:00:00 -0400

Lobe Sciences plans $2.1M private placement to fund S-100 development

Wed, 12 Aug 2026 08:46:11 -0400

Lobe Sciences Ltd. (CSE: LOBE, OTCQB: LOBEF, FSE: LOBE.F) announced a non-brokered private placement of 24,705,880 common shares at $0.085 per share, for aggregate gross proceeds of approximately $2,100,000.

According to a press release, the company intends to use the net proceeds to fund cash reserves, advance clinical development of the S-100 molecule being developed by its subsidiary Applied Lipid Technologies Inc., and for working capital and general corporate purposes.

S-100 is Applied Lipid Technologies' lead asset, currently targeting sickle cell disease as its initial indication. The company has stated it intends to evaluate S-100's potential eligibility for orphan-drug designation and for

Lobe Sciences Ltd. Announces Non-Brokered Private Placement

Wed, 12 Aug 2026 08:45:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

VANCOUVER, BC / ACCESS Newswire / August 12, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, is pleased to announce a non-brokered private placement offering of 24,705,880 common shares in the capital of the Company ("Common Shares") at a price of $0.085 per Common Share, for aggregate gross proceeds of approximately $2,100,000 (the "Private Placement").

The Company intends to use the net proceeds of the Private

Lobe Sciences Ltd. Announces Non-Brokered Private Placement

Wed, 12 Aug 2026 08:45:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

The Company intends to use the net proceeds of the Private

Lobe Sciences Announces Results of Annual General and Special Meeting of Shareholders

Wed, 05 Aug 2026 08:00:00 -0400

Shareholders Approve All Matters Presented at Meeting, Including New Long-Term Incentive Plan and Amendment to Constating Documents

VANCOUVER, BC / ACCESS Newswire / August 5, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, today announced the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held on July 30, 2026.

A total of 152,807,032 common shares were represented at the Meeting, representing approximately 49.6% of the Company's issued and outstanding common shares as of the June

Lobe Sciences Announces Results of Annual General and Special Meeting of Shareholders

Wed, 05 Aug 2026 08:00:00 -0400

Shareholders Approve All Matters Presented at Meeting, Including New Long-Term Incentive Plan and Amendment to Constating Documents

A total of 152,807,032 common shares were represented at the Meeting, representing approximately 49.6% of the Company's issued and outstanding common shares as of the June

Lobe Sciences Files Management Information Circular for Annual General and Special Meeting on July 30, 2026

Tue, 07 Jul 2026 06:00:00 -0400

The Company's Annual General and Special Meeting will be held on Thursday, July 30, 2026, at 11:00 a.m. (Vancouver time), at 15^th Floor, 1111 West Hastings Street, Vancouver, British Columbia, with virtual attendance available via Microsoft Teams
Dr. Frederick D. Sancilio, Executive Chairman and Chief Executive Officer, provided a letter to shareholders including an update on corporate strategy with a focus on uplisting to a senior exchange and an overview of progress across the Company's three subsidiary programs
Shareholders will be asked to vote on the election of directors, appointment of auditors, approval of a new

Lobe Sciences Files Management Information Circular for Annual General and Special Meeting on July 30, 2026

Tue, 07 Jul 2026 06:00:00 -0400

The Company's Annual General and Special Meeting will be held on Thursday, July 30, 2026, at 11:00 a.m. (Vancouver time), at 15^th Floor, 1111 West Hastings Street, Vancouver, British Columbia, with virtual attendance available via Microsoft Teams
Dr. Frederick D. Sancilio, Executive Chairman and Chief Executive Officer, provided a letter to shareholders including an update on corporate strategy with a focus on uplisting to a senior exchange and an overview of progress across the Company's three subsidiary programs
Shareholders will be asked to vote on the election of directors, appointment of auditors, approval of a new

Lobe Sciences Directors and Management Increase Equity Ownership Through Settlement of Accrued Fees by the Issuance of Common Shares

Tue, 09 Jun 2026 06:00:00 -0400

Directors and management elected to receive restricted equity in place of accrued fees payable, thereby increasing ownership and further aligning with shareholders
The Canadian Securities Exchange has accepted the share issuance, allowing the Company to complete the settlement
Company remains well-positioned with C$4.96 million in cash and short-term investments as of its most recent quarter ended February 28, 2026
Subsidiary R&D programs remain on track and on budget, with continued de-risking through Lobe's disciplined development model

VANCOUVER, BC / ACCESS Newswire / June 9, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F), a clinical-stage biopharmaceutical company advancing

Lobe Sciences Directors and Management Increase Equity Ownership Through Settlement of Accrued Fees by the Issuance of Common Shares

Tue, 09 Jun 2026 06:00:00 -0400

Directors and management elected to receive restricted equity in place of accrued fees payable, thereby increasing ownership and further aligning with shareholders
The Canadian Securities Exchange has accepted the share issuance, allowing the Company to complete the settlement
Company remains well-positioned with C$4.96 million in cash and short-term investments as of its most recent quarter ended February 28, 2026
Subsidiary R&D programs remain on track and on budget, with continued de-risking through Lobe's disciplined development model

VANCOUVER, BC / ACCESS Newswire / June 9, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F), a clinical-stage biopharmaceutical company advancing

Lobe Sciences Announces Proposed Shares for Debt Transaction

Mon, 01 Jun 2026 22:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / June 1, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates for diseases with significant unmet medical needs, under a disciplined, pharmaceutical development platform, progressing assets from early development to clinical stages, through focused subsidiary companies, today announced that it has entered into agreements to settle C$1,372,761.20 in outstanding management and director fee debt through the issuance of an aggregate of 12,749,643 common shares of the Company (the "Settlement Shares") at a price of $0.11 per Settlement Share (the "Debt

Lobe Sciences Announces Proposed Shares for Debt Transaction

Mon, 01 Jun 2026 22:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / June 1, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates for diseases with significant unmet medical needs, under a disciplined, pharmaceutical development platform, progressing assets from early development to clinical stages, through focused subsidiary companies, today announced that it has entered into agreements to settle C$1,372,761.20 in outstanding management and director fee debt through the issuance of an aggregate of 12,749,643 common shares of the Company (the "Settlement Shares") at a price of $0.11 per Settlement Share (the "Debt

Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York

Wed, 06 May 2026 20:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. ("Lobe", or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates through a disciplined pharmaceutical development platform, progressing assets from early development to the clinic through focused subsidiary companies, today announced that its Chief Executive Officer, Dr. Frederick D. Sancilio, will be attending the D. Boral Capital Global Conference being held on May 7, 2026 at The Plaza Hotel in New York City.
Dr. Sancilio will be available for meetings with institutional investors, pharmaceutical companies, and potential